Pfizer Seeks FDA Authorization For COVID-19 Pill

Drug company Pfizer has submitted its COVID-19 pill treatment to the U.S. Food and Drug Administration (FDA) for authorization to be used for certain people.

On Tuesday, Pfizer announced that “it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID™ […] for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death.”

“If authorized or approved, PAXLOVID would be the first oral antiviral of its kind … that could be prescribed as an at-home treatment to high-risk patients at the first sign of infection, potentially helping patients avoid severe illness which can lead to hospitalization and death,” the announcement noted.

The Wall Street Journal reported, “Initial supplies of Pfizer’s pill would be limited. Pfizer projects it will manufacture more than 180,000 courses of treatment this year, and plans to increase production to at least 50 million courses next year.” – READ MORE

Related Articles

(PREMIUM) PAINE IN THE MORNING: 11 things you need to know this Monday – January 3, 2022

  There is also an ad free audio version of this episode you can listen to HERE. Hospital ERs filled with symptom-less, COVID-positive people in one state – Emergency rooms in Vermont are being overwhelmed with people who have tested positive for COVID but have no symptoms, bolstering the criticism that mass testing amid a…

To access this post, you must purchase The Hot Wire, The Hot Wire (DG), Monthly Supporter​ or Monthly Supporter​ (DG).